Summary
Regeneron Pharmaceuticals, Inc. reported mixed results for the first quarter of 2025. Total revenues decreased slightly year-over-year to $3.03 billion from $3.15 billion, primarily driven by a significant decline in U.S. EYLEA sales due to competitive pressures and the transition to EYLEA HD. However, this was partially offset by strong growth in Dupixent and a solid performance from EYLEA HD in the U.S. Net income increased to $808.7 million, or $7.27 per diluted share, compared to $722.0 million, or $6.27 per diluted share, in the prior year's quarter. This improvement was supported by an increase in collaboration revenue, particularly from Sanofi, and a favorable shift in other income (expense), net. The company also announced its first quarterly cash dividend and continued its share repurchase program, signaling a commitment to returning capital to shareholders.
Financial Highlights
46 data points| Revenue | $3.03B |
| R&D Expenses | $1.33B |
| SG&A Expenses | $633.00M |
| Operating Expenses | $2.44B |
| Operating Income | $591.70M |
| Net Income | $808.70M |
| EPS (Basic) | $7.58 |
| EPS (Diluted) | $7.27 |
| Shares Outstanding (Basic) | 106.70M |
| Shares Outstanding (Diluted) | 111.20M |
Key Highlights
- 1Total revenues declined 3.7% to $3.03 billion, mainly due to a 39% drop in U.S. EYLEA sales.
- 2Net income rose 12% to $808.7 million, with diluted EPS increasing to $7.27 from $6.27.
- 3Collaboration revenue increased 27% to $1.18 billion, driven by strong performance in the Sanofi collaboration (Dupixent and Kevzara).
- 4U.S. EYLEA HD sales showed strong growth, up 111% to $306.8 million, though total EYLEA and EYLEA HD sales declined 16% due to the drop in EYLEA.
- 5Research and development expenses increased by 6.3% to $1.33 billion.
- 6The company declared its first quarterly cash dividend of $0.88 per share.
- 7Regeneron continued its share repurchase program, buying back $1.05 billion of common stock in the quarter.